Sofinnova Investments
Sofinnova Investments is a US healthcare investment firm managing approximately $4.6B across a private venture capital platform (Funds IV–XII) and the Synergy Fund public-equity hedge fund, backing late preclinical and clinical therapeutic companies in the US and Europe. The firm has funded 118 companies, producing 55 IPOs, 30 M&As, and 33 FDA approvals, including the $14B Karuna→BMS exit.
- Company typePrivate
- Founded1972
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sofinnova Investments does
Sofinnova Investments is a US healthcare investment firm headquartered at 3000 Sand Hill Road in Menlo Park, California, founded in 1972 in Paris and operating in the US since 1976. Following the 1997 separation of the original Sofinnova group into independent US (Sofinnova Ventures) and Paris (Sofinnova Partners) entities, Sofinnova Investments has been the US successor firm. The firm invests in late preclinical and clinical therapeutic companies across the US and Europe in oncology, respiratory, dermatology, ophthalmology, neurology, and women's health, with a cumulative track record of 118 companies funded, 55 IPOs, 30 M&As, and 33 FDA drug approvals. Notable exits include Karuna Therapeutics→Bristol Myers Squibb ($14B), CinCor→AstraZeneca ($1.8B), RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Principia→Sanofi, and Capstan→AbbVie (June 2025).
The firm operates a two-platform model: a private-markets venture capital platform organized around successive fund vintages (Funds IV through XII, with Fund X at $650M in 2016 the largest disclosed), and a public-markets platform (Synergy Fund) launched in 2017 as an all-cap, value-oriented, long/short global therapeutics hedge fund with emphasis on mid- and small-cap companies. Approximately $4.6B in assets under management and committed capital is managed as of 9/30/2025. Revenue is generated via management fees on committed capital plus performance-based carried interest on exits; LPs access information through a dedicated Investor Portal. Sofinnova's investment team is "mostly comprised of doctors and doctorate holders," and partners hold meaningful board seats in portfolio companies, providing operational support across drug development, FDA/EMA navigation, company building, and IPO/M&A execution. The firm operates regional offices in Boston (Seaport) and New York, with a previously opened La Jolla office whose current operational status is unconfirmed; a tier-1 co-investor ecosystem includes Viking Global Investors, ARCH Venture Partners, Fidelity, Forbion, Novo Holdings, B Capital, RA Capital, Mubadala, and Perceptive Advisors.
Sofinnova Investments firmographics
Firmographics- Name
- Sofinnova Investments
- Legal name
- Sofinnova Investments, Inc.
- Website
- https://sofinnova.com
- Company type
- Private
- Founded year
- 1972
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sofinnova Investments is a US healthcare investment firm managing approximately $4.6B across a private venture capital platform (Funds IV–XII) and the Synergy Fund public-equity hedge fund, backing late preclinical and clinical therapeutic companies in the US and Europe. The firm has funded 118 companies, producing 55 IPOs, 30 M&As, and 33 FDA approvals, including the $14B Karuna→BMS exit.
- Ownership category
- akta.pro rank
Sofinnova Investments industry classification
Industry- Product category
- Venture Capital - Healthcare/Biotech Investment
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Endowment / OCIO-Style Multi-Manager Platforms (FSANAGAG)
Keywords
Where Sofinnova Investments is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Sofinnova Investments business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Private Equity Investment Returns: Primary revenue stream: capital appreciation and exit proceeds from investments in late preclinical and clinical therapeutic companies across the U.S. and Europe. Realized through IPOs (e.g., Karuna, CinCor, RayzeBio, Aerovate, Bolt, Athira, Vera, Inozyme, NuCana, Principia, Entasis, Iterum, Y-mAbs, Ascendis, Apellis) and M&A acquisitions (e.g., Karuna→BMS $14B, CinCor→AstraZeneca $1.8B, RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Tesaro→GSK, Principia→Sanofi, Promedior→Roche, Capstan→AbbVie, Gyroscope→Novartis). 55 IPOs and 30 M&As to date.
- Public Equity Hedge Fund: All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with emphasis on mid and small-cap companies. Generates management fees and performance-based returns through the Synergy Fund and related public equity strategies.
- Fund Management Fees & Carry: Sofinnova raises successive venture funds (Funds IV through XII, with Fund X being the largest at $650M in 2016) and charges typical private equity management fees and performance carry against approximately $4.6B in assets under management and committed capital (as of 9/30/2025).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Venture Fund X (2016) — largest disclosed fund |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Sofinnova Investments product offering
Product offeringCore offering
Sofinnova Investments is a healthcare-focused investment firm that deploys human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe. It operates a two-platform architecture: a Private Markets venture capital platform that partners with biotech entrepreneurs through every stage of company formation (initial funding, management team building, corporate alliances, IPO and M&A), and a Public Markets hedge fund (Synergy Fund) that pursues an all-cap, value-oriented, long/short global therapeutics strategy.
Product overview
Sofinnova Investments operates a two-platform architecture: a Private Markets venture capital platform and a Public Markets hedge fund (Synergy Fund). The Private Markets platform is the core offering, deploying human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe, with key therapeutic areas including oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. The Public Markets platform, launched in 2017, is an all-cap, value-oriented, long/short global therapeutics hedge fund with an emphasis on mid- and small-cap companies. Limited partners access fund information through the Sofinnova Investor Portal (powered by Altareturn). Sofinnova manages approximately $4.6B in assets under management and committed capital, has funded 118 companies, achieved 55 IPOs, 30 M&As, and 33 FDA drug approvals, with 120 years of operating experience and 100 years of investing experience.
Differentiator
Problem solved
Functional benefit
Products and services
- Private Markets Platform Venture capital platform partnering with biotech entrepreneurs in the U.S. and Europe, guiding them through all stages of company formation including initial funding, management team building, corporate alliances, M&A, and IPO. Invests in late preclinical and clinical therapeutic companies across oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. Successive funds IV through XII raised since 1998.
- Public Markets (Synergy Fund) All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with an emphasis on mid- and small-cap companies. The fund is managed by the Public Equity team led by General Partner Eric Delbridge, MD.
- Sofinnova Investor Portal
Quantifiable outcome
- 118 companies funded; 55 IPOs; 30 M&As; 33 FDA drugs approved
- +13 more outcomes
Companies that use Sofinnova Investments
Customer profileSegments3 records
Ideal customer profiles3 records
Sofinnova Investments technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sofinnova Investments partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core.
- Galapagos NVcoreOriginally developed COL-5671 (a SIK3 inhibitor) and fully transferred it to Coultreon Biopharma in April 2025 with an initial seed investment, then participated in Coultreon's $125M Series A. Strategic asset-transfer and co-investor relationship connected to Sofinnova via Coultreon.
- Fosun PharmacoreGranted Expedition Therapeutics (Sofinnova portfolio) exclusive worldwide rights (excluding parts of China) to develop and commercialize EXPD-101, a DPP1 inhibitor for COPD.
- AbbViecoreAcquired Capstan Therapeutics (Sofinnova portfolio) in 2025 to strengthen commitment to transforming patient care in immunology, representing a major strategic exit.
- BiogencoreEntered partnership with City Therapeutics (Sofinnova portfolio) worth up to $1 billion in May 2025, per Fierce Biotech coverage. City Therapeutics planned to supplement its raise through additional partnerships similar to its existing Biogen deal.
- GSKcoreAcquired Aiolos Bio (Sofinnova portfolio) in January 2024. Previously acquired TESARO (Sofinnova portfolio). Strategic acquirer of Sofinnova-backed respiratory and oncology assets.
- Bristol Myers SquibbcoreAcquired Karuna Therapeutics for $14B (Sofinnova Managing Partner Jim Healy served as board member) and RayzeBio (acquired by BMS to add premier radiopharmaceutical platform). Marquee Sofinnova M&A exit partner.
- AstraZenecacoreAcquired CinCor Pharma (Sofinnova portfolio, Jim Healy was Chairman) for $1.8B; the CinCor acquisition was completed in February 2023. AstraZeneca also subsequently acquired ZS Pharma (Sofinnova portfolio).
- NovartiscoreAcquired Gyroscope Therapeutics (Sofinnova portfolio) for up to $1.5B to expand its ophthalmology gene therapy capabilities; Gyroscope acquisition completed February 2022. Novartis also previously acquired Ziarco (Sofinnova portfolio).
- Eli LillycoreAcquired Akouos (Sofinnova portfolio, completed Dec 2022) to expand efforts in genetic hearing loss treatments. Previously partnered with NextCure (Sofinnova portfolio) on immuno-oncology discovery (Nov 2018) and with BioAge (Sofinnova portfolio) on multi-year collaboration for age-related disease targets (Dec 2024).
- RegeneroncoreCompleted acquisition of Checkmate Pharmaceuticals (Sofinnova portfolio) in May 2022. Strategic acquirer of Sofinnova-backed immuno-oncology assets.
- PfizercoreAcquired Amplyx Pharmaceuticals (Sofinnova portfolio, completed Apr 2021) and NextWave Pharmaceuticals (Sofinnova portfolio) for pediatric ADHD therapeutics. Acquired Metsera (referenced in 2026 outlook context as a $10B obesity biotech acquisition).
- MerckcoreAcquired VelosBio (Sofinnova portfolio) in November 2020 to add ROR1-directed antibody drug conjugates for oncology.
- SanoficoreCompleted acquisition of Principia Biopharma (Sofinnova portfolio) in September 2020. Also partnered with Gyroscope Therapeutics for up to $60M investment (Nov 2021).
- RochecoreAcquired Promedior (Sofinnova portfolio, completed Feb 2020) and Spark Therapeutics (Sofinnova portfolio, completed in 2019-2020). Multiple Sofinnova M&A exits.
- AstellascoreAcquired Audentes Therapeutics (Sofinnova portfolio) in 2020, completing the acquisition January 15, 2020. Marquee Sofinnova M&A exit in gene therapy.
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
Sofinnova Investments competitors and assessment
Company assessmentDirect peers
- OrbiMed Advisors: Large healthcare-dedicated investment firm across private equity, public equity, and royalty/credit strategies. Comparable to Sofinnova in being a healthcare-only, multi-strategy platform investing across therapeutic stages with a doctor/PhD-led team.
- Atlas Venture: Early-stage, healthcare-focused venture firm that partners with entrepreneurs to build therapeutics companies. Comparable to Sofinnova's clinical-stage therapeutics focus and company-creation model, though Atlas skews earlier-stage.
- Versant Ventures: Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics with a strong company-creation arm. Comparable to Sofinnova in its therapeutics focus, scientific team, and U.S./Europe footprint.
- 5AM Ventures: Early-stage healthcare venture firm focused on building therapeutic platforms from inception. Comparable to Sofinnova in its emphasis on founding-stage biotech and its scientific founder partnership model.
- Frazier Life Sciences: Healthcare-dedicated venture and growth firm investing across therapeutics and medtech. Comparable to Sofinnova in therapeutics focus and in backing clinical-stage companies through to IPO and M&A.
- RA Capital Management: Healthcare-focused crossover fund investing across public and private therapeutics. Comparable to Sofinnova's two-platform (private + public) model and frequent co-investment with Sofinnova in late-stage rounds.
- ARCH Venture Partners: Healthcare and technology venture firm known for early-stage biotech creation and long-duration partnerships. Comparable to Sofinnova as a deep-science VC that co-invests in many of the same portfolio companies.
- Forbion: European healthcare-dedicated venture firm investing in late preclinical and clinical-stage therapeutics. Comparable to Sofinnova in transatlantic therapeutic focus and frequent co-investment (e.g., Coultreon, Capstan).
- Venrock: Healthcare and technology venture firm with a long history of therapeutics investing. Comparable to Sofinnova in clinical-stage biotech focus and the use of deep scientific expertise to back therapeutic entrepreneurs.
Broad incumbents
- New Enterprise Associates (NEA): Large, multi-stage venture firm with a sizable healthcare practice alongside technology. Comparable to Sofinnova in healthcare venture investing but operates as a generalist with a broader sector mandate and much larger overall AUM.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Sofinnova Investments social profiles
Digital presenceSofinnova Investments compliance and trust
Trust signalCompliance1 record
Sofinnova Investments financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sofinnova Investments leadership team
Management profileNumber of profiles
Profiles20 records
Sofinnova Investments subsidiaries and ownership
Company hierarchySubsidiaries1 record
Sofinnova Investments funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sofinnova Investments M&A and investment
M&A and investmentM&A
Investments323 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sofinnova Investments
What does Sofinnova Investments do?
Sofinnova Investments is a healthcare-focused investment firm that deploys human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe. It operates a two-platform architecture: a Private Markets venture capital platform that partners with biotech entrepreneurs through every stage of company formation (initial funding, management team building, corporate alliances, IPO and M&A), and a Public Markets hedge fund (Synergy Fund) that pursues an all-cap, value-oriented, long/short global therapeutics strategy.
Is Sofinnova Investments a public or private company?
Sofinnova Investments is a private company. It is classified as management employee owned and is currently operating.
When was Sofinnova Investments founded?
Sofinnova Investments was founded in 1972. It employs 11 to 50 people.
Where is Sofinnova Investments based?
Sofinnova Investments is headquartered in Menlo Park, United States, in the North America region.
How does Sofinnova Investments make money?
Three revenue lines are on record. Private Equity Investment Returns are the primary driver. The others are public Equity Hedge Fund and fund Management Fees & Carry.
Who are Sofinnova Investments's main competitors?
Direct peers on record are OrbiMed Advisors, Atlas Venture, Versant Ventures, 5AM Ventures, Frazier Life Sciences, RA Capital Management, ARCH Venture Partners, Forbion and Venrock. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Sofinnova Investments have an API?
No public API is recorded for Sofinnova Investments.
What industry is Sofinnova Investments in?
Sofinnova Investments's product category is Venture Capital - Healthcare/Biotech Investment. Its primary akta.pro industry code is FSANAGAG, Endowment / OCIO-Style Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.